News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Kalkine Media Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
S&CO Inc. has acquired a new stake in AstraZeneca Plc, purchasing 37,990 shares valued at approximately $7.1 million during the second quarter. Institutional investors now collectively own 20.35% of AstraZeneca's stock. Analysts maintain a "Moderate Buy" rating for AstraZeneca, with an average price target …
Walleye Capital LLC has acquired 128,006 shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) during the second quarter, a position valued at approximately $3.82 million. Despite this acquisition and a consensus "Buy" rating from analysts with an average price target of $66, the company reported a …
Wall Street Zen downgraded Maze Therapeutics (NASDAQ:MAZE) from a "hold" to a "sell" rating, despite a broader analyst consensus of "Buy" with an average price target of $66.00. The company's shares opened at $27.18, representing a 1.8% decrease and significantly below its 52-week high …
Harold Bernstein, President, R&D & CMO at Maze Therapeutics, Inc. (NASDAQ:MAZE), sold 16,142 shares of company stock for $445,620 on August 13, 2026. This transaction followed an exercise of stock options at a lower price and was conducted under a Rule 10b5-1 trading plan. …
Maze Therapeutics' CMO, Harold Bernstein, sold 16,142 shares of company stock worth $445,680.62 under a pre-arranged Rule 10b5-1 plan, reducing his ownership by 50%. This follows a previous sale of 14,609 shares in July. Despite the insider selling and the company's ongoing unprofitability with …
Maze Therapeutics' President, R&D & CMO, Harold Bernstein, exercised 16,142 stock options and subsequently sold the resulting shares on August 13, 2026, under a Rule 10b5-1 trading plan. The options were exercised at $10.42 per share, and the common shares were sold at a …
A group of Battery Ventures funds and certain managing members have filed an updated beneficial-ownership report for Braze, Inc. (BRZE), indicating that as of June 30, 2026, no single reporting person owns 5% or more of Braze’s Class A common stock. The filing details …
ParaZero Technologies Ltd. (PRZO) has announced a separation agreement with its Vice President of Global Sales, Bat-Sheva Noy, effective August 17, 2026. The company stated that her departure is not due to any disagreements with operations, policies, or practices, and ParaZero does not expect …
This article provides financial information for Trailblazer Acquisition Corp. (BOATS:BLZRW), specifically focusing on its price to sales forward ratio. It is presented within the context of TradingView's platform, offering an overview of the company's financials.
This article provides a comprehensive overview of Trailblazer Acquisition Corp.'s (BLZR) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider trading forms. It highlights key filings from 2026, detailing Meteora Capital's ownership stakes and Trailblazer Acquisition Corp.'s financial performance …
This article provides an analysis of Trailblazer Acquisition Corp. Class A Ordinary Shares (NASDAQ: BLZR), including its stock price, key financial metrics, and corporate profile. As of the last update, BLZR traded at $10.18, showing a slight increase. The company is a SPAC focused …
AstraZeneca PLC (AZN) shares fell 2.12% to £114.60 on Friday, underperforming the broader market as the FTSE 100 Index also declined. The company's stock closed significantly below its 52-week high, which was achieved earlier in the year.
Key Points Earlier this month, AstraZeneca and Bristol Myers Squibb became the subject of merger rumors. Investors reacted negatively to the rumors, even if on paper such a deal would create an oncology-focused big pharma powerhouse worth around $400 billion. Considering regulatory uncertainty and …
Maze Therapeutics, Inc. has announced the appointments of Dr. Paula Johnson and Dr. Sophie Kornowski to its Board of Directors. Dr. Johnson brings extensive experience in cardiology and leadership from Wellesley College and Johnson & Johnson, while Dr. Kornowski contributes over 35 years of …
Maze Therapeutics, a clinical-stage biopharmaceutical company, has appointed Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., to its Board of Directors. These appointments bring extensive clinical, research, and biopharmaceutical leadership experience to the company. Maze Therapeutics is advancing its pipeline of small molecule …
Braze Chief Business Officer Astha Malik sold 33,656 shares of the company's Class A Common Stock for $930,588 on August 10, 2026, as part of a pre-arranged trading plan. Following the sale, Ms. Malik beneficially owns 278,138 shares. This insider transaction occurred as Braze …
This page from TradingView provides financial information for Beazer Homes USA, Inc. under the ticker BX:BE4A on the BX Swiss exchange. It lists the company's "Price to earnings forward" value and highlights the fact that the market is currently closed with no trades.
Zacks Research has upgraded Beazer Homes USA (NYSE:BZH) from "hold" to "strong-buy," despite a broader analyst consensus of "Hold." The company's shares opened at $33.19, close to their 52-week high, and have shown substantial institutional ownership, with major investors increasing their positions. Other analysts, …
Wealthcare Advisory Partners LLC acquired 12,112 shares of AstraZeneca Plc, valued at approximately $2.3 million, in the second quarter. This move is part of a broader trend of institutional investors increasing their holdings in the pharmaceutical company, which now has 20.35% institutional ownership. AstraZeneca …
Beazer Homes USA Inc. agreed to a buyout by Dream Finders Homes Inc. for $33.50 a share, totaling $915 million, largely due to shareholder pressure for a near-term cash premium. The article also covers other Jacksonville-area companies' financial results, including Rayonier Advanced Materials, Fidelity …
Search by ticker symbol or company name and select a result to open its chart.